In the rapidly evolving field of regenerative medicine, Juvena Therapeutics stands out not just for its technology, but for its mission-driven leadership. Under the guidance of co-founder and CEO Dr. Hanadie Yousef, Juvena has emerged as a pioneer in developing biologics for rare and chronic diseases through a novel AI-enabled discovery platform. With the company’s recent regulatory and funding milestones, Juvena is carving a path at the intersection of artificial intelligence, protein science, and regenerative healthcare.
From Discovery to Designation: Juvena’s Breakthrough Year
Juvena Therapeutics capped off 2022 with a $41 million Series A financing round, led by Mubadala Capital and Horizons Ventures, aimed at scaling its AI-driven discovery platform for secreted-protein therapeutics. The investment marked a pivotal moment in Juvena’s development, giving the company the resources to expand its pipeline and move its first lead candidate, JUV-161, toward the clinic.
In January 2024, the FDA granted Orphan Drug Designation to JUV‑161 for the treatment of myotonic dystrophy type 1 (DM1), a debilitating neuromuscular disorder with no FDA-approved therapies. This recognition not only affirms the scientific and therapeutic merit of Juvena’s approach, but also positions the company for accelerated development timelines and seven years of market exclusivity upon approval.
At the helm of Juvena is Dr. Hanadie Yousef, a biologist and entrepreneur whose academic pedigree and leadership accolades are quickly earning her recognition across the biotech industry. With a PhD from UC Berkeley and postdoctoral work at Stanford University focused on aging and stem cell biology, Dr. Yousef has long been fascinated by the regenerative potential of secreted proteins.
Her leadership has earned her a place among Business Insider’s 30 Leaders Under 40, and Endpoints News’ 20 Under 40. Most recently, she was recognized as a Rising Leader by In Vivo in 2024.
What sets Dr. Yousef apart is her ability to bridge cutting-edge science with commercial strategy. Her vision is to use Juvena’s AI-enhanced platform to unlock the therapeutic power of the secretome—those proteins secreted by human stem cells that can modulate inflammation, regeneration, and disease progression.
A Platform Like No Other: Harnessing AI for Protein-Based Regeneration
Juvena’s differentiator lies in its computationally-enabled discovery platform, designed to map and screen secreted proteins from stem cells with therapeutic potential. The platform combines high-throughput phenotypic screening, multi-omics integration, and machine learning to pinpoint candidates that drive tissue regeneration or metabolic correction.
The company’s lead program, JUV‑161, targets muscle regeneration, while a second candidate, JUV‑112, is in preclinical development for metabolic and obesity-related disorders. According to Dr. Yousef, Juvena’s approach allows for “precision protein therapeutics that replicate the beneficial effects of cell therapy without the complexity or risk”.
Beyond its $41M Series A, Juvena has steadily gained validation across both scientific and regulatory arenas. The company’s Orphan Drug designation for JUV‑161 not only de-risks the development path but also underscores the unmet need in DM1. Juvena was also spotlighted by the National Institute on Aging’s small business program for its regenerative medicine potential.
Recognition of Dr. Yousef’s leadership over the past year adds further credibility as the company prepares for its next phase. With first-in-human trials anticipated in the near future, Juvena is transitioning from platform-building to translational execution.
Regenerative Medicine’s Next Frontier
Juvena’s secreted-protein approach is timely. As biologics gain traction in orphan indications, muscle diseases, and metabolic disorders, few competitors are specifically focused on the secretome as a drug discovery engine. The regenerative medicine market, expected to surpass $150 billion by 2030, is shifting from cell therapies to more scalable and controllable alternatives—an opportunity Juvena is uniquely positioned to exploit.
While competitors such as Alector and Denali focus on neurodegeneration or inflammation, Juvena’s niche in muscle regeneration and metabolic reprogramming with protein-based therapeutics offers a relatively uncluttered path. Their AI-first, biology-led strategy enables rapid iteration and de-risking before clinical investment.
Strategic Path Forward
Juvena’s commercial and regulatory strategy is deliberately platform-first. By advancing JUV‑161 through FDA’s orphan pathway, the company is setting the stage for accelerated development and potential partnerships. Regulatory incentives like fast-track designation, combined with early engagement from big pharma, could facilitate future licensing deals.
Meanwhile, the company is expected to file its first IND application soon, a major milestone that will unlock access to human data and allow Juvena to further validate its approach. Additional disclosures about metabolic pipeline candidates, like JUV‑112, are also anticipated later this year.
As with any ambitious biotech startup, challenges remain. Scaling the AI discovery infrastructure while simultaneously advancing multiple therapeutic programs will require capital efficiency and operational discipline. The next funding round—or a strategic partnership—will be crucial in bridging the gap from preclinical to clinical-stage biotech.
Still, the momentum is undeniable. With a clear scientific thesis, regulatory tailwinds, and an accomplished CEO at the helm, Juvena Therapeutics is not just developing drugs—it’s redefining what’s possible in regenerative biologics.